Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr Lin on the Selection of Systemic Therapy in HER2+ Breast Cancer With Brain Metastases

August 7th 2023

Nancy U. Lin, MD, discusses selecting between systemic vs local therapy for patients with HER2-positive breast cancer displaying central nervous system metastases.

ADCs, CDK4/6 Inhibitors, and SERDs Broaden HR+ and Triple-Negative Breast Cancer Treatment Paradigms

August 4th 2023

Novel data with trastuzumab deruxtecan, sacituzumab govitecan, and ribociclib have demonstrated an influx of overall survival advantages compared with standard-of-care regimens across breast cancer patient subsets, including HER2-positive, hormone receptor–positive, and triple-negative disease.

Dr Abdou on Treatment Sequencing With CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

August 4th 2023

Yara Abdou, MD, discusses treatment sequencing with CDK4/6 inhibitors across all lines of therapy in patients with hormone receptor–positive, HER2-negative breast cancer.

HER2+ mBC: Emerging Agents in the Third-Line and Higher Setting

August 3rd 2023

Debu Tripathy, MD, discusses novel therapies being developed for later-line treatment of HER2+ mBC.

Key Findings from the NATALEE Trial

August 3rd 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the NATALEE trial, which evaluated adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.

Risk of Recurrence

August 3rd 2023

Stephanie Graff, MD, describes her impression of the case and discusses the risk for recurrence in this particular patient.

T-DXd: Updated Results from the DESTINY-Breast Studies and Practical Considerations for Followup

August 3rd 2023

Drs McArthur and Telli discuss recent data updates from the DESTINY-Breast trials of T-DXd, including a pooled analysis, and share best practices for monitoring patients for lung complications.

Dr Abdou on Considerations Between AKT vs PI3K Inhibition in HR+/HER2– Breast Cancer

August 2nd 2023

Yara Abdou, MD, discusses the considerations between AKT inhibitors vs PI3K inhibition in patients with hormone receptor-positive, HER2-negative breast cancer.

Time to Treatment Initiation Affected by Demographics, Socioeconomics in Solid Tumors

August 2nd 2023

Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of TTI, according to findings from a retrospective cohort study published in JCO Oncology Practice.

Breast Nerve Preservation and Grafting: How Surgeons Can Help Mitigate Sensation Loss

August 1st 2023

More surgeons are having in-depth conversations with their patients with breast cancer and prophylactic patients about the fact that nerves will have to be cut during their mastectomy, how that will impact sensation and quality of life, and how surgeon collaboration and breast neurotization can help restore sensation.

Potential Approaches to Treatment Switching in HR+/HER2- mBC

August 1st 2023

Experts share how they approach management of patients with disease progression on first-line endocrine therapy, with a focus on ESR1 mutation testing and identifying who might be suitable for treatment with the oral SERD elacestrant.

Ribociclib/ET versus Chemotherapy in Premenopausal Patients: RIGHT Choice

August 1st 2023

Timothy Pluard, MD, discusses recent data from an age-based subgroup analysis of RIGHT Choice, which compares the efficacy of combination ribociclib/ET versus chemotherapy in the first-line treatment of HR+/HER2- advanced breast cancer.

Neoadjuvant Pembrolizumab Plus Chemotherapy Improves pCR Rate in High-Risk, Early-Stage ER+/HER2– Breast Cancer

July 28th 2023

Neoadjuvant pembrolizumab plus chemotherapy led to an improvement in pathological complete response rate compared with chemotherapy plus placebo in patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.

Sacituzumab Govitecan Wins Approval in Europe for Pretreated HR+/HER2– Metastatic Breast Cancer

July 28th 2023

The European Commission has approved sacituzumab govitecan-hziy for the treatment of adult patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the advanced setting

Dr Waks on Later-Line Treatment Options in HER2+ Breast Cancer

July 28th 2023

Adrienne G. Waks, MD, discusses treatment alternatives in the third line and beyond for patients with metastatic HER2-positive breast cancer.

Neighborhood Plays an Important Role in Clinical Outcomes for Patients With Breast Cancer

July 28th 2023

Addressing socioeconomic health disparities has been a crucial objective of health policy in the United States. The relationship between cancer incidence and mortality and socioeconomic status varies across malignancies.

Dr Tarantino on the Impact of Emerging ADCs in HR+ Breast Cancer

July 27th 2023

Paolo Tarantino, MD, discusses the evolution and impact of the continued investigation of antibody-drug conjugates in the treatment of patients with hormone receptor–positive breast cancer.

Dr Wander on Using Platinum Chemotherapy Wisely in Breast Cancer

July 27th 2023

Seth Wander, MD, PhD, discusses challenges related to the ongoing platinum chemotherapy shortage for patients with breast cancer and other malignancies, as well as ways that oncologists and cancer centers can operate during the shortage to continue to provide appropriate care for patients.

Dr Han on the Investigation of Neoadjuvant Therapy Plus a Dendritic Cell Vaccine in HER2+ Breast Cancer

July 27th 2023

Heather Han, MD, discusses initial safety and efficacy results from the phase 2 NATASHA trial in patients with early-stage HER2-positive breast cancer.

Remaining Unmet Needs in the Third-Line and Lessons from HER2CLIMB

July 27th 2023

Drs Tripathy and Kaklamani emphasize the most critical unmet needs for patients with HER2+ metastatic breast cancer in the third-line or higher settings and recap what the field previously learned from the HER2CLIMB trial of tucatinib/trastuzumab/capecitabine.